Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer
Information source: Bristol-Myers Squibb
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Carcinoma, Non-Small-Cell Lung
Intervention: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL (Drug); Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Bristol-Myers Squibb Official(s) and/or principal investigator(s): Bristol-Myers Squibb, Study Director, Affiliation: Bristol-Myers Squibb
Summary
The purpose of this study is to determine the maximum tolerated dose, dose-limiting
toxicity, and recommended Phase II dose of ixabepilone in combination with carboplatin in
patients with non-small cell lung cancer.
Clinical Details
Official title: A Phase I Study of Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer as First-line Treatment
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Number of Participants With Dose-limiting Toxicity (DLT)Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose of Carboplatin in Combination With Ixabepilone, 32 mg/m^2
Secondary outcome: Number of Participants With Death as Outcome, Treatment-related Serious Adverse Events (SAEs), SAEs, Adverse Events (AEs), and Treatment-related AEs Leading to DiscontinuationNumber of Participants With Grade 3 or Greater Treatment-related AEs Number of Participants With Abnormalities in Hematology Laboratory Values by Worst CTC Grade Number of Participants With Abnormalities in Serum Chemistry Laboratory Values by Worst CTC Grade Number of Participants With Abnormalities in Urine Testing Results by Worst CTC Grade Number of Participants With Abnormalities in Blood Pressure and Heart Rate Number of Participants With Abnormalities in Weight and Eastern Cooperative Oncology Group (ECOG) Performance Status Number of Participants at Each Response Evaluation Criteria in Solid Tumors (RECIST) Assessment Maximum Observed Plasma Concentration of Ixabepilone Time of Maximum Observed Plasma Concentration of Ixabepilone Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time of Ixabepilone Volume of Distribution at Steady State of Ixabepilone Total Body Clearance of Ixabepilone
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age ≥20 years
- Histologic or cytologic diagnosis of advanced non-small cell lung cancer (NSCLC)
- Advanced NSCLC, defined as stage IIIB (without indications for radiotherapy), stage
IV, or recurrent
- No prior chemotherapy-containing regimens for the treatment of NSCLC
- Eastern Cooperative Oncology Group performance status of 0-1
- Life expectancy of at least 12 weeks
- Accessible for treatment and follow up; patients who could be hospitalized for first
15 days of Cycle 1
- Adequate recovery from previous systemic therapy (at least 3 weeks for surgery or
radiation therapy)
Exclusion Criteria:
- Women of childbearing potential (WOCBP) unwilling or unable to use an acceptable
method to avoid pregnancy for study period and for up to 4 weeks after last dose of
study drug
- Women pregnant or breast feeding
- Women with a positive pregnancy test result on enrollment or prior to study drug
administration
- Sexually active fertile men not using effective birth control for the entire study
period and for up to 3 months after the last dose of study drug if their partners are
WOCBP
- Patients with symptomatic or requiring treatment for brain metastases and/or
leptomeningeal metastases
- Prior radiation must not have included ≥30% of major bone-marrow-containing areas
(pelvis, lumbar spine)
- Common Terminology Criteria (CTC) Grade 2 or greater neuropathy
- Psychiatric or other disorders rendering the patient incapable of complying with
protocol requirements
- Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in
situ of the cervix (Patients with a history of malignancy but without evidence of
disease for 5 years are eligible)
- Serious uncontrolled medical disorder or active systemic infection that would
impair the ability of the subject to receive protocol therapy.
- Myocardial infarction, unstable angina, or unstable congestive heart failure within 6
months
- Known history of infection with human immunodeficiency virus
- Inadequate bone marrow function
- Inadequate hepatic function
- Inadequate renal function
- Known prior severe hypersensitivity reaction (CTC Grade 2 or greater) to agents
containing Cremophor®EL
- Known severe hypersensitivity reaction to agents containing carboplatin and other
platinum
- Prior treatment with an epothilone and/or with platinum
- History of high-dose chemotherapy with bone marrow transplant or peripheral blood
stem cell support within 2 years
- On treatment with strong Cytochrome P450 3A4 inhibitor
- Current imprisonment
- Compulsorily detention for treatment of psychiatric or physical illness
Locations and Contacts
Local Institution, Chuo-Ku, Tokyo 104-0045, Japan
Additional Information
BMS Clinical Trials Disclosure Investigator Inquiry form For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm
Starting date: June 2008
Last updated: March 15, 2011
|